Glenmark Therapeutics Inc., USA, has announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump-pack presentations in the United States. The new pump-pack format is designed to provide consumers with a more convenient and easy-to-use dispensing option. The launch adds to Glenmark’s growing dermatology portfolio in the U.S. market.
Adapalene Gel USP, 0.1% contains the same active ingredient as Differin® Gel, 0.1%, and is marketed by Glenmark for the indications specified in its approved Drug Facts label.
According to Nielsen® syndicated data for the 52-week period ending September 5, 2026, the U.S. Differin® Gel, 0.1% OTC market recorded approximately 45.8 million USD in annual sales. The market data includes the brand and available therapeutic equivalents.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America, Glenmark, said the new pump pack is intended to enhance the consumer experience by providing a convenient dispensing option while strengthening the company's U.S. dermatology portfolio. Kikuchi further highlighted that the launch reflects Glenmark's focus on providing high-quality and affordable healthcare solutions that respond to changing consumer needs.
Glenmark clarified that its Adapalene Gel USP, 0.1% OTC product is marketed only for the indications listed in Glenmark's approved drug facts label. The company's product may therefore have labeling differences compared with the approved indications of the reference listed drug (RLD).
Glenmark also stated that its adapalene product is not manufactured or distributed by Galderma Laboratories, L.P. or Galderma Holding S.A., the distributor and trademark owner associated with Differin®, respectively. Galderma does not manufacture or license Glenmark's product.
The launch represents another addition to Glenmark's U.S. dermatology offerings, with the new pump-pack presentation aimed at improving convenience for consumers using OTC adapalene gel.
